Following its third-quarter report, Vanguard Health Care Fund (Trades, Portfolio)Â holds 73 stocks with a total value of $46.245 billion. The following are the sales with the largest impacts on its portfolio.
The guru reduced its stake in Amgen Inc. (AMGN) by 46.83% with an impact of -0.78% on the portfolio.
It is a biotechnology company that discovers, develops, manufactures and delivers human therapeutics, its only business segment. During the third quarter total revenues grew 2% year over year, and GAAP operating income increased 8%. The company reported a 10% increase for GAAP EPS and an 11% increase for non-GAAP EPS.
GuruFocus gives the stock a profitability and growth rating of 9 out of 10 with ROE of 26.05% and ROA of 10.20% that are outperforming 91% of the companies in the Global Biotechnology industry. Financial strength has a rating of 6 out of 10 with cash to debt of 1.06 that is far below the industry median of 49.39.
The largest shareholder among the gurus is PRIMECAP Management (Trades, Portfolio) with 3.85% of outstanding shares followed by Jim Simons (Trades, Portfolio) with 0.16%, First Eagle Investment (Trades, Portfolio) with 0.13%, Joel Greenblatt (Trades, Portfolio) with 0.07%, David Carlson (Trades, Portfolio) with 0.06% and Samuel Isaly (Trades, Portfolio) with 0.05%.
The guru trimmed its stake in Merck & Co. Inc. (MRK) by 10.72% with an impact of -0.61% on the portfolio.
It is a health care company that delivers health solutions through its prescription medicines, vaccines, biologic therapies, animal health and consumer care products. During the third quarter worldwide sales grew 5%, GAAP EPS was 78 cents and non-GAAP EPS was $1.07.
GuruFocus gives the stock a profitability and growth rating of 6 out of 10 with ROE of 12.26% and ROA of 5.48% that are outperforming 62% of the companies in the Global Drug Manufacturers - Major industry.
The firm holds 1.68% of outstanding shares in the company and is the largest shareholder among the gurus followed by Barrow, Hanley, Mewhinney & Strauss with 0.96%, Dodge & Cox with 0.88%, Ken Fisher (Trades, Portfolio) with 0.24%, T Rowe Price Equity Income Fund (Trades, Portfolio) with 0.12%, PRIMECAP Management (Trades, Portfolio) with 0.11% and Simons with 0.11%.
The firm reduced its stake in UnitedHealth Group Inc. (UNH) by 5.64% with an impact of -0.38% on the portfolio.
The company designs products, provides services and applies technologies that improve access to health and well-being services, simplify the health care experience and make health care more affordable. Third quarter revenues increased 12% year over year and earnings from operations grew 19%. Net earnings were $2.03 per share; adjusted net earnings grew 23% year over year to $2.17 per share
GuruFocus gives the stock a profitability and growth rating of 7 out of 10 with ROE of 18.61% and ROA of 5.64% that are outperforming 56% of the companies in the Global Health Care Plans industry. Financial strength has a rating of 6 out of 10 with cash to debt of 0.47 that is below the industry median of 0.97.
Another notable shareholder among the gurus is Dodge & Cox with 2.25% of outstanding shares followed by Jeremy Grantham (Trades, Portfolio) with 0.56%, Chris Davis (Trades, Portfolio) with 0.37%, Barrow, Hanley, Mewhinney & Strauss with 0.27%, Bill Nygren (Trades, Portfolio) with 0.25%, Sarah Ketterer (Trades, Portfolio) with 0.15 and Tom Gayner (Trades, Portfolio) with 0.07%.
The guru trimmed its stake in Boston Scientific Corp. (BSX) by 13.24% with an impact of -0.35% on the portfolio.
The company is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. Third-quarter sales increased 11% on a reported basis and 10% on an operational basis, all compared to the prior-year period, and organic revenue grew 9%.
GuruFocus gives the stock a profitability and growth rating of 5 out of 10 with ROE of 1.27% and ROA of 0.45% that are outperforming 54% of the companies in the Global Medical Devices industry. Financial strength has a rating of 4 out of 10 with cash to debt of 0.04 that is below the industry median of 2.34.
PRIMECAP Management (Trades, Portfolio) is another notable shareholder among the gurus with 3.13% of outstanding shares followed by Simons with 0.36%, Diamond Hill Capital (Trades, Portfolio) with 0.36%, Isaly with 0.29%, Pioneer Investments (Trades, Portfolio) with 0.22%, Steven Cohen (Trades, Portfolio) with 0.14% and Michael Price (Trades, Portfolio) with 0.07%.
The firm reduced its stake in Baxter International Inc. (BAX) by 30.49% with an impact of -0.21% on the portfolio.
It is a health care company. It develops, manufactures and markets products that save and sustain the lives of people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma and other chronic conditions. During the third quarter worldwide sales totaled $2.6 billion, an increase of 3% on a reported basis and 4% on a constant currency basis as compared to the prior-year period.
GuruFocus gives the stock a profitability and growth rating of 4 out of 10 with ROE of 58.40% and ROA of 23.58% that are outperforming 97% of the companies in the Global Medical Instruments & Supplies industry.
The largest shareholder among the gurus is Daniel Loeb (Trades, Portfolio) with 9.54% of outstanding shares followed by Richard Pzena (Trades, Portfolio) with 0.57%, Tweedy Browne (Trades, Portfolio) with 0.44%, First Eagle Investment (Trades, Portfolio) with 0.39%, Mairs and Power (Trades, Portfolio) with 0.36%, Tweedy Browne (Trades, Portfolio) Global Value with 0.16%, Greenblatt with 0.16% and Leucadia National (Trades, Portfolio) with 0.13%.
The firm trimmed its stake in Biogen Inc. (BIIB) by 4.98% with an impact of -0.1% on the portfolio.
It is a biopharmaceutical company. The company discovers, develops, manufactures and markets therapies for neurological, autoimmune and hematologic disorders. Total revenues increased 6% versus the same quarter in the prior year; GAAP net income grew 7%, and GAAP diluted earnings per share (EPS) increased 13% versus the same quarter in the prior year.
GuruFocus gives the stock a profitability and growth rating of 9 out of 10 with ROE of 36.11% and ROA of 18.58% that are outperforming 98% of the companies in the Global Biotechnology industry. Financial strength has a rating of 6 out of 10 with cash to debt of 0.66 that is below the industry median of 49.39.
PRIMECAP Management (Trades, Portfolio) is the largest shareholder among the gurus with 7.37% of outstanding shares followed by Andreas Halvorsen (Trades, Portfolio) with 1.48%, Frank Sands (Trades, Portfolio) with 1.37%, Spiros Segalas (Trades, Portfolio) with 0.42% and Ketterer with 0.22%.
The guru reduced its stake in Anthem Inc. (ANTM) by 8.74% with an impact of -0.09% on the portfolio.
It is a health benefits company that offers a spectrum of network-based managed care plans to the large and small employer, individual, Medicaid and Medicare markets.
GuruFocus gives the stock a profitability and growth rating of 8 out of 10 with ROE of 9.90% is underperforming and ROA of 3.67% that is outperforming 54% of the companies in the Global Health Care Plans industry. Financial strength has a rating of 6 out of 10 with cash to debt of 0.10 that is below the industry median of 0.97.
The largest shareholder among the gurus is Barrow, Hanley, Mewhinney & Strauss with 3.26% of outstanding shares followed by Larry Robbins (Trades, Portfolio) with 1.5%, Dodge & Cox with 1.22%, HOTCHKIS & WILEY with 0.94%, First Eagle Investment (Trades, Portfolio) with 0.89%, T Rowe Price Equity Income Fund (Trades, Portfolio) with 0.8% and Simons with 0.45%.
Disclosure: I do not own any shares of any stocks mentioned in this article.
Start a free seven-day trial of Premium Membership to GuruFocus.
